Baron Funds: “Bio-Techne (TECH) Can Still Generate Strong Revenue Growth”

Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index (the “Benchmark”) and the 4.60% decline for the S&P 500 Index. Try to spend some time taking a look at the fund’s top 5 holdings to be informed about their best picks for 2022.

In its Q1 2022 investor letter, Baron Health Care Fund mentioned Bio-Techne Corporation (NASDAQ:TECH) and explained its insights for the company. Founded in 1976, Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis, Minnesota-based biotech company with a $12.7 billion market capitalization. Bio-Techne Corporation (NASDAQ:TECH) delivered a -37.34% return since the beginning of the year, while its 12-month returns are down by -26.54%. The stock closed at $324.18 per share on June 14, 2022.

Here is what Baron Health Care Fund has to say about Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2022 investor letter:

“Bio-Techne Corporation is a leading provider of life sciences tools, such as high-quality purified proteins and protein analysis tools, which are sold to biomedical researchers and clinical research laboratories. Shares fell in concert with a broad rotation out of high-growth and life sciences tools stocks that had performed well in 2021. We continue to believe Bio-Techne can generate strong revenue growth driven by its research reagents, cell and gene therapy tools, and protein platform business.”

Our calculations show that Bio-Techne Corporation (NASDAQ:TECH) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Bio-Techne Corporation (NASDAQ:TECH) was in 29 hedge fund portfolios at the end of the first quarter of 2022, compared to 24 funds in the previous quarter. Bio-Techne Corporation (NASDAQ:TECH) delivered a -20.07% return in the past 3 months.

In May 2022, we also shared another hedge fund’s views on Bio-Techne Corporation (NASDAQ:TECH) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.

Disclosure: None. This article is originally published at Insider Monkey.